The impact of weight gain on quality of life among persons with schizophrenia.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Psychiatric Services

• Publication date

  2003-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1176/APPI.PS.54.4.565PMID 12663847
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Obesity as a risk factor for antipsychotic noncompliance.

  2004cited by this paper
• Health-related quality of life among obese persons seeking and not currently seeking treatment.

  2000cited by this paper
• Adherence to antipsychotic medications.

  1999cited by this paper
• The distribution of body mass index among individuals with and without schizophrenia.

  1999cited by this paper
• Extent of distress caused by adverse experiences associated with antipsychotic treatment

  1999cited by this paper
• Antipsychotic-induced weight gain: a comprehensive research synthesis.

  1999cited by this paper
• Clinical Management of Clozapine Patients in Relation to Efficacy and Side-Effects

  1992cited by this paper
• Assessment of quality of life in clinical trials of cardiovascular therapies

  1985cited by this paper

• Improved quality of life with semaglutide in schizophrenia: Secondary analyses from a randomized controlled trial.

  2026cites this paper
• Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the 5-Week, Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials.

  2025cites this paper
• Bibliometric Insights Into the Dynamics of Schizophrenia and Obesity Research

  2025cites this paper
• Factors associated with clinically relevant weight loss in men and women with psychotic disorders.

  2025cites this paper
• The role of anti-inflammatory diets and supplementation in metabolic syndrome and symptom remission in adults with schizophrenia: a systematic review

  2025cites this paper
• Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.

  2025cites this paper
• Developing a Holistic Inpatient Wellness Program (Mesra) in Mental Health Care Center: A Study in Hospital Mesra Bukit Padang

  2024cites this paper
• Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial

  2024cites this paper
• Metabolic side effects in persons with schizophrenia during mid‐ to long‐term treatment with antipsychotics: a network meta‐analysis of randomized controlled trials

  2023cites this paper
• Influence of psychopathology and metabolic parameters on quality of life in patients with first-episode psychosis before and after initial antipsychotic treatment

  2023cites this paper
• Weight stigma interventions as future avenues for stigma resistance: comment on Dubreucq et al.

  2023cites this paper
• Polygenic risk scores enhance prediction of body mass index increase in individuals with a first episode of psychosis

  2023cites this paper
• Calorie-restricted diet mitigates weight gain and metabolic abnormalities in obese women with schizophrenia: a randomized controlled trial

  2023cites this paper
• Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia

  2023cites this paper
• Leveraging genetics to improve Body Mass Index increase prediction in the first-episode of psychosis

  2022cites this paper
• Evaluating the Effectiveness of Joint Specialist Case Conferences in Improving Diabetes Control in Patients With Schizophrenia on Clozapine

  2022cites this paper
• Pharmacological interventions for prevention of weight gain in people with schizophrenia.

  2022cites this paper
• Investigating the risk of severe adverse events in gabapentinoid users with chronic non-cancer pain in English primary care of drug – drug interactions in older community-dwellers: A systematic review and meta-analysis

  2022cites this paper
• Twelve-month outcomes in overweight/obese users with mental disorders following a multi-element treatment including diet, physical activity, and positive thinking: The real-world “An Apple a Day” controlled trial

  2022cites this paper
• Prediction of quality of life in schizophrenia using machine learning models on data from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial

  2022cites this paper
• Effect of 5‐HT2C receptor gene polymorphism (HTR2C−759C/T) on metabolic adverse effects in Thai psychiatric patients treated with risperidone

  2021cites this paper
• An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder

  2021cites this paper
• Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials

  2021cites this paper
• Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis

  2021cites this paper
• NDT_A_313840 2885..2904

  2021cites this paper
• Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies

  2021cites this paper
• Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology

  2021cites this paper
• Associations of the SREBF2 Gene and INSIG2 Polymorphisms with Obesity and Dyslipidemia in Thai Psychotic Disorder Patients Treated with Risperidone

  2021cites this paper
• Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials.

  2020cites this paper
• The relationship between schizophrenia patients' attitudes towards physical health and the prevalence of metabolic syndrome

  2020cites this paper
• Body Mass Index of Schizophrenic Patients with Combined Antipsychotic Therapy

  2020cites this paper
• Obesity in Chinese patients with chronic schizophrenia: Prevalence, clinical correlates and relationship with cognitive deficits.

  2020cites this paper
• A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort)

  2020cites this paper
• Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia

  2020cites this paper
• Prévention et prise en charge du diabète de type 2 chez les patients souffrant de schizophrénie traités par antipsychotiques de seconde génération

  2020cites this paper
• The Psychology of Food Cravings in Patients With First-Episode Psychosis

  2020cites this paper
• Pharmacological interventions for reduction of weight gain in people with schizophrenia

  2019cites this paper
• A comprehensive cardiovascular disease risk profile in patients with schizophrenia

  2019cites this paper
• “Looking Forward”: a qualitative evaluation of a physical activity program for middle-aged and older adults with serious mental illness

  2019cites this paper
• Meta-analysis of physical activity and effects of social function and quality of life on the physical activity in patients with schizophrenia

  2019cites this paper
• Pharmacological interventions for prevention of weight gain in people with schizophrenia

  2019cites this paper
• The Effects of Antipsychotic Drugs (Olanzapine and Risperidone) on Body Weight, Body Fat Percentage and Lipid Profiles of Patients with Psychotic Illness

  2019cites this paper
• Changes in Health‐Related Quality of Life in People With Intellectual Disabilities Who Discontinue Long‐Term Used Antipsychotic Drugs for Challenging Behaviors

  2018cites this paper
• Schizophrenias’ Quality of Life and Emotional Intelligence in Songklanagarind Hospital

  2018cites this paper
• Physical activity, lifestyle-related factors and psychological determinants among patients with schizophrenia.

  2018cites this paper
• Health-related quality of life in people with intellectual disability who use long-term antipsychotic drugs for challenging behaviour.

  2018cites this paper
• Examining the Relationship between Body Mass Index and Health-Related Quality of Life Perception among People with Mental Illness

  2018cites this paper
• Weight management in men with mental health problems

  2018cites this paper
• Enhancing metabolic monitoring for children and adolescents using second‐generation antipsychotics

  2018cites this paper
• TREATMENT WITH PREGABALIN BY OLE SCHJERNING

  2018cites this paper
• Association of lifestyle-related factors and psychological factors on quality of life in people with schizophrenia.

  2018cites this paper
• An ounce of prevention outweighs kilograms of weight loss.

  2018cites this paper
• Anxiety in Schizophrenia: Treatment with Pregabalin

  2018cites this paper
• Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study

  2018cites this paper
• Quality of life in Chinese patients with schizophrenia: A meta-analysis.

  2018cites this paper
• The “Double Whammy”: Women's Experiences of Weight Gain After Diagnosis and Treatment for Schizophrenia Spectrum Disorders

  2018cites this paper
• Minimizing Weight Gain for Patients Taking Antipsychotic Medications: The Potential Role for Early use of Metformin

  2017cites this paper
• Pregabalin for anxiety in patients with schizophrenia - A randomized, double-blind placebo-controlled study.

  2017cites this paper
• Prevalence of Metabolic Syndrome amongst Bipolar Patients on Lithium andSodium Valproate Monotherapy

  2017cites this paper
• Exercise Treatments for Psychosis: a Review

  2017cites this paper
• Is there a ‘weight neutral’ second-generation antipsychotic for bipolar disorder?

  2017cites this paper
• Quality of life and clinical characteristics in a nonselected sample of patients with schizophrenia

  2016cites this paper
• Guidelines on the management of co-occurring alcohol and other drug and mental health conditions in alcohol and other drug treatment settings.

  2016cites this paper
• Beyond Assessment of Quality of Life in Schizophrenia: Cultural, Clinical, and Research Perspectives from India, a Case Study

  2016cites this paper
• Dealing with the ‘double-whammy’: women’s experiences of schizophrenia and weight gain

  2016cites this paper
• Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study

  2016cites this paper
• Quality of life and physical activity levels in outpatients with schizophrenia

  2016cites this paper
• Adjunctive &agr;-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study

  2016cites this paper
• Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes

  2016cites this paper
• Lifestyle related factors & impact of metabolic syndrome on quality of life, level of functioning & self-esteem in patients with bipolar disorder & schizophrenia

  2016cites this paper
• Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders.

  2016cites this paper
• L’éducation thérapeutique du patient pour les clientèles psychiatriques présentant un surpoids : l’exemple du programme « Wellness » développé au Québec

  2016cites this paper
• [Psychoeducation for overweight patients with psychiatric disorders: The Wellness program developed in Quebec].

  2016cites this paper
• Prevalence of overweight in schizophrenia patients in Asia: findings of the research on Asian psychotropic prescription patterns (REAP) study.

  2016cites this paper
• Attitudes toward metabolic adverse events among patients with schizophrenia in Japan

  2016cites this paper
• A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia

  2016cites this paper
• Place de la chirurgie bariatrique par sleeve gastrectomie chez le patient bipolaire obèse : nouvelles perspectives

  2015cites this paper
• Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms.

  2015cites this paper
• Physical Activity and Quality of Life of Outpatients with Schizophrenia.

  2015cites this paper
• Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial

  2015cites this paper
• Effects of Social Networks on Physical Health Among People with Serious Mental Illness

  2014cites this paper
• Cognitive illness representation as perceived by persons with schizophrenia in Bangladesh

  2014cites this paper
• Effects of a group physical activity program on physical fitness and quality of life in individuals with schizophrenia

  2014cites this paper
• Pharmacological interventions for reducing weight gain in schizophrenia

  2014cites this paper
• A CONTRIBUTION TO DESIGNING EFFECTIVE AND ENJOYABLE PHYSICAL ACTIVITY PROGRAMS FOR INDIVIDUALS WITH SCHIZOPHRENIA

  2014cites this paper
• Body Mass Index, Obesity, and Psychopathology in Patients With Schizophrenia

  2014cites this paper
• Exercise Capacity and Quality of Life in Patients with Schizophrenia

  2013cites this paper
• A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight

  2013cites this paper
• Body mass index and quality of life among outpatients with schizophrenia in Japan

  2013cites this paper
• Soccer practice as an add-on treatment in the management of individuals with a diagnosis of schizophrenia

  2013cites this paper
• Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sample

  2013cites this paper
• Attitude towards second‐generation antipsychotics among patients with schizophrenia and their relatives

  2013cites this paper
• Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1).

  2013cites this paper
• Efficacité des programmes de modifications des habitudes de vie pour la gestion de poids des personnes avec des troubles psychiatriques

  2013cites this paper
• Open-label pilot study on vitamin D3 supplementation for antipsychotic-associated metabolic anomalies

  2013cites this paper
• ESTUDIO MULTIDISCIPLINAR DE SEGUIMIENTO DEL PESO CORPORAL EN UNA COHORTE DE PACIENTES EN TRATAMIENTO INICIAL CON ANTIPSICÓTICOS MULTIDISCIPLINARY FOLLOW-UP STUDY OF BODY WEIGHT IN A COHORT OF PATIENTS WITH ONSET OF ANTIPSYCHOTIC TREATMENT

  2013cites this paper
• Finite mixture regression model analysis on antipsychotics induced weight gain: investigation of the role of the serotonergic genes.

  2013cites this paper
• Behavioural interventions for reducing weight gain in schizophrenia

  2013cites this paper
• Addressing Obesity in Schizophrenia: An Ecological Approach

  2013cites this paper
• Bridging the gap from evidence to policy and practice: Reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication

  2013cites this paper